Table 2.

Thirty-day mortality correlated to selected characteristics

Characteristic (n = 292)	n	Died (%)		OR (95% CI)				p-value	adj. OR (95% CI)				adj. p-value
Male sex	201	40 (19.9)		0.59 (0.33–1.04)				0.07	0.35 (0.17–0.74)				0.006
Age 18–49 years	22	2 (9.1)		1.00
Age 50–59 years	36	6 (16.7)		2.00 (0.37–10.92)				0.42	2.72 (0.39–19.08)				0.31
Age 60–69 years	62	14 (22.6)		2.92 (0.61–14.03)				0.18	3.21 (0.51–20.03)				0.21
Age 70–79 years	83	20 (24.1)		3.17 (0.68–14.78)				0.14	3.58 (0.58–22.17)				0.17
Age ≥80 years	89	25 (28.1)		3.91 (0.85–17.95)				0.08	6.60 (1.13–38.49)				0.04
Comorbidity (n = 235)
Pulmonary disease	49	18 (36.7)		2.58 (1.29–5.14)				0.01	3.05 (1.34–6.94)				0.008
COPD	24	8 (33.3)		1.89 (0.76–4.69)				0.20	0.61 (0.16–2.37)				0.47
Cystic fibrosis	1	0 (0.0)
Heart disorder	87	22 (25.3)		1.33 (0.71–2.49)				0.42	1.50 (0.64–3.51)				0.35
Peripheral vascular disease	55	13 (23.6)		1.14 (0.56–2.34)				0.71	2.26 (0.96–5.30)				0.06
Vascular graft	15	1 (6.7)		0.24 (0.03–1.83)				0.20	0.18 (0.02–1.69)				0.13
Diabetes mellitus	63	9 (14.3)		0.49 (0.22–1.08)				0.08	0.46 (0.22–0.96)				0.04
Renal failure	42	10 (23.8)		1.12 (0.51–2.46)				0.84	1.96 (0.74–5.17)				0.18
Chronic liver disease	9	3 (33.3)		1.79 (0.43–7.40)				0.42	1.27 (0.22–7.21)				0.79
Neurological paresis	3	1 (33.3)		1.16 (0.12–11.36)				1.00	7.61 (0.45–128.36)				0.16
Immunosuppression	52	11 (21.2)		0.91 (0.43–1.93)				0.85	0.75 (0.26–2.18)				0.59
Chemotherapy in the last 6 months	52	12 (23.1)		1.05 (0.50–2.19)				1.00	0.21 (0.07–0.66)				0.007
Solid malignancy	73	20 (27.4)		1.55 (0.81–2.94)				0.23	0.99 (0.37–2.68)				0.98
Metastasis	39	14 (35.9)		2.33 (1.11–4.90)				0.03	7.12 (2.32–21.79)				0.001
Haematologic disease	42	11 (26.2)		1.63 (0.74–3.59)				0.28	5.47 (1.85–16.17)				0.002
Neutropaenia	38	11 (28.9)		1.51 (0.69–3.30)				0.30	1.33 (0.41–4.28)				0.63
AIDS	1	0 (0.0)
Burn wounds	6	2 (33.3)		1.77 (0.32–9.95)				0.62	4.08 (0.45–36.68)				0.21
Composite comorbidity score (n = 235)
Charlson score ≤4	44	4 (9.1)		1.00
Charlson score 5–8	119	27 (22.7)		2.93 (0.96–8.94)				0.06	2.91 (0.95–8.92)				0.06
Charlson score 9–12	49	13 (26.5)		3.61 (1.08–12.08)				0.04	3.67 (1.09–12.41)				0.04
Charlson score ≥13	21	8 (38.1)		6.15 (1.59–23.82)				0.009	7.05 (1.79–27.86)				0.005
Healthcare-related (n = 235)
Urinary catheter >1 week	88	18 (20.5)		0.87 (0.45–1.65)				0.75	1.09 (0.50–2.39)				0.82
Surgery last month	48	9 (18.8)		0.76 (0.34–1.69)				0.56	0.98 (0.38–2.51)				0.96
Hospitalised >1 week	82	20 (24.4)		1.21 (0.64–2.29)				0.62	1.61 (0.76–3.41)				0.22
Resident at nursing home	33	8 (24.2)		1.15 (0.48–2.72)				0.82	1.16 (0.41–3.32)				0.78
Polymicrobial infection	90	22 (24.4)		1.13 (0.62–2.02)				0.68	2.52 (1.18–5.40)				0.02
Origin of infection (n = 235)
Urinary tract	82	12 (14.6)		0.37 (0.18–0.75)				0.005	0.28 (0.12–0.65)				0.003
Respiratory tract	44	17 (38.6)		2.81 (1.38–5.70)				0.003	2.81 (1.13–7.01)				0.03
Wound	38	12 (31.6)		1.81 (0.84–3.90)				0.13	1.99 (0.81–4.92)				0.13
Central venous catheter	9	0 (0.0)
Other/unknown	50	11 (22.0)		0.99 (0.47–2.11)				0.98	1.16 (0.47–2.83)				0.75

Patient characteristics correlated to 30-day mortality and presented with odds ratio (OR), adjusted odds ratio (adj. OR) and 95% confidence interval (95% CI). The multivariable model contained age, sex, pulmonary disease, vascular graft, peripheral vascular disease, chemotherapy in the last 6 months, haematological diseases including malignancies, metastasis, diabetes mellitus and neurological paresis. Significant values are in bold font